<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556722</url>
  </required_header>
  <id_info>
    <org_study_id>GPB/2017/9585500</org_study_id>
    <nct_id>NCT03556722</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM)</brief_title>
  <acronym>Magnet-EM</acronym>
  <official_title>Effectiveness and Tolerability of Repetitive Transcranial Magnetic Stimulation For Preventive Treatment Of Episodic Migraine: A Single Centre, Randomised, Double-Blind, Sham-Controlled Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Putra Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Putra Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of repetitive transcranial magnetic
      stimulation (rTMS) as new preventive treatment of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine patients according to International Headache Society criteria will be allocated
      randomly into two treatment arms. One group will receive active rTMS and another group will
      receive sham rTMS for treatment phase (5 sessions). Assessment will be made at baseline,
      month 1, month 2 and month 3 post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm parallel assignment involves two groups of participants. One group receives r-TMS, and the other group receives sham placebo r-TMS.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean monthly migraine days.</measure>
    <time_frame>Baseline and month 1, 2 and 3 post treatment</time_frame>
    <description>The mean monthly migraine days will be calculated using the monthly migraine days from each of the month of the double-blind treatment phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean monthly migraine attacks.</measure>
    <time_frame>Baseline and month 1, 2 and 3 post treatment</time_frame>
    <description>The mean monthly migraine attacks will be calculated using the monthly migraine attack from each of the month of the double-blind treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least a 50% reduction from baseline in mean monthly migraine days.</measure>
    <time_frame>Baseline and month 1, 2 and 3 post treatment</time_frame>
    <description>Change from baseline in mean monthly pain intensity of migraine attacks. The mean monthly pain intensity will be based on the record of the maximal pain intensity by means of a verbal scale (i.e. 0 =no headache; 1 = mild headache; 2 = moderate headache; 3 = severe headache) prior to taking symptomatic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events in response to rTMS.</measure>
    <time_frame>During treatment and up until 1 month post treatment</time_frame>
    <description>Recorded any adverse events as per Good Clinical Practice Guideline and Declaration of Helsinki.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Depression Anxiety Stress Scale (DASS 21) score changes in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean score changes from baseline for depression, anxiety and stress category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Migraine Disability Assessment Test (MIDAS) score changes in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean score changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Migraine Specific Questionnaire (MSQ) version 2.1 score changes in migraine patients in response to r-TMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean score changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The EQ-5D score changes in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean score changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pittsburgh Sleep Quality Index score changes in migraine in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean score changes from baseline for sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Food Frequency Questionnaire score changes in migraine in response to rTMS.</measure>
    <time_frame>Baseline</time_frame>
    <description>Measuring food frequency intake at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Global Physical Activity Questionnaire score change in migraine in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean score changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcranial Doppler (TCD) pattern changes in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Mean flow velocity (cm/s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography (EEG) pattern change in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>EEG pattern differences based on report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum serotonin level in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Serum serotonin (ng/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum beta-endorphin level changes in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Serum beta endorphin (ng/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcitonin gene related peptide (CGRP) level in migraine patients in response to rTMS.</measure>
    <time_frame>Baseline and at month 3 post treatment</time_frame>
    <description>Serum CGRP (pg/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction measures of efficacy, tolerability, safety and expectations of rTMS among the participants.</measure>
    <time_frame>At month 3 post treatment</time_frame>
    <description>A 5-point, Likert scale will be used to evaluate satisfaction with rTMS in migraine prevention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham repetitive Transcranial Magnetic Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation.</intervention_name>
    <description>High frequency rTMS on left dorsolateral prefrontal cortex.</description>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation</arm_group_label>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham rTMS</intervention_name>
    <description>Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.</description>
    <arm_group_label>Sham repetitive Transcranial Magnetic Stimulation</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Males or females aged 18 to 60 years of age.

          2. Subjects fulfilling criteria for episodic migraine as per the Third Edition of The
             International Headache Society (ICHD-3) for at least 1 year.

          3. Frequency of migraine attacks 2-8 times per month with less than 15 headache days per
             month for at least 3 months prior to screening.

          4. Demonstrated compliance with the headache diary during the run-in period by entry of
             headache data on a minimum of 24/30 days (80% compliance).

          5. A signed and dated informed consent document indicating that the subject has been
             informed of all pertinent aspects of the study including any known and potential risks
             and available alternative treatments.

        Exclusion criteria:

          1. Patients with previous history of rTMS treatment.

          2. Onset of headache at more than 50-year-old.

          3. Headache with red flags symptoms that may suggest organic secondary headaches.

          4. Pregnant or lactating women.

          5. Patients with contraindications to TMS such as metallic implant and pacemaker based on
             the Screening 13-item Questionnaire for rTMS candidate.

          6. Patients with medical conditions such severe hypertension, infections, malignancy,
             cardiovascular and cerebrovascular disease, epilepsy degenerative central nervous
             system diseases, renal failure, hepatic failure, bleeding diathesis and serious mental
             illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamidon B. Basri</last_name>
    <role>Study Chair</role>
    <affiliation>University Putra Malaysia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan Aliaa B. Wan Sulaiman, MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Universiti Putra Malaysia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wan Aliaa B. Wan Sulaiman, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Putra Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wan Aliaa B. Wan Sulaiman, MRCP</last_name>
    <phone>+60386092980</phone>
    <phone_ext>+ 60134888405</phone_ext>
    <email>wanaliaa@upm.edu.my</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nabil Izzaatie B. Mohamad Safiai, Master</last_name>
    <phone>+60189474202</phone>
    <email>nabil.izzaatie@student.upm.edu.my</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Putra Malaysia</name>
      <address>
        <city>Serdang</city>
        <state>Selangor</state>
        <zip>43400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan Aliaa B. Wan Sulaiman, MRes</last_name>
      <phone>+603 8609 2980</phone>
      <email>wanaliaa@upm.edu.my</email>
    </contact>
    <investigator>
      <last_name>Nabil Izzaatie B. Mohamad Safiai, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nur Ain B. Amir, Degree</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Putra Malaysia</investigator_affiliation>
    <investigator_full_name>Wan Aliaa Wan Sulaiman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>Transcranial Doppler</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Pain</keyword>
  <keyword>Migraine prophylaxis</keyword>
  <keyword>Dorsolateral Prefrontal Cortex</keyword>
  <keyword>Protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

